Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

CASI Acquires Anti-CD19 T-cell Therapy from Juventas

contractpharmaJune 18, 2019

Tag: CASI , Anti-CD19 , T-cell , Juventas , CNCT19

PharmaSources Customer Service